What are the potential interactions between etifoxine and propranolol (beta-blocker)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Etifoxine and Propranolol Interaction

Direct Answer

There are no documented clinically significant pharmacokinetic or pharmacodynamic interactions between etifoxine and propranolol, and these medications can be used together with standard monitoring for beta-blocker effects.


Pharmacological Basis for Safety

Etifoxine's Mechanism and Metabolism

  • Etifoxine is a non-benzodiazepine anxiolytic that works through GABA-A receptor modulation, both directly via β2/β3 subunits and indirectly through neurosteroid production via TSPO (translocator protein) binding 1
  • Unlike benzodiazepines, etifoxine does not cause significant sedation, psychomotor impairment, or withdrawal syndromes 1
  • The drug's effects are not completely reversed by flumazenil, indicating a distinct mechanism from benzodiazepines 1

Propranolol's Metabolic Profile

  • Propranolol is a non-selective beta-blocker metabolized primarily through CYP2D6 and CYP3A4 pathways 2
  • The drug affects both beta-1 and beta-2 receptors throughout the body 2, 3

Why No Interaction Exists

  • Etifoxine does not inhibit or induce cytochrome P450 enzymes that metabolize propranolol
  • The GABA-ergic mechanism of etifoxine does not interfere with beta-adrenergic receptor blockade
  • No shared metabolic pathways create competition for drug clearance

Standard Beta-Blocker Monitoring Applies

Cardiovascular Parameters to Monitor

  • Heart rate: Watch for bradycardia (HR <60 bpm), which is a propranolol effect, not an interaction 2
  • Blood pressure: Monitor for hypotension, particularly in patients on higher propranolol doses 2, 3
  • Cardiac conduction: Be alert for heart block in susceptible patients 2, 3

Propranolol-Specific Contraindications

  • Cardiogenic shock, marked sinus bradycardia, second or third-degree heart block without pacemaker, and decompensated heart failure remain absolute contraindications 2, 3
  • These contraindications are unrelated to etifoxine co-administration

Clinical Considerations for Combined Use

When This Combination Makes Sense

  • Patients with anxiety disorders (treated with etifoxine) who have comorbid hypertension, migraine, essential tremor, or post-myocardial infarction requiring beta-blockade 2, 1
  • Etifoxine offers anxiolytic effects without the dependence risk of benzodiazepines, making it preferable for longer-term anxiety management 1, 4

Dosing Recommendations

  • Etifoxine: Standard dose of 150 mg/day for up to 12 weeks 1, 4
  • Propranolol: Dose according to indication (80-160 mg/day for most indications) 2
  • No dose adjustments needed for either medication when used together

Adverse Effects to Anticipate

  • From etifoxine: Initial drowsiness is most common, but this typically resolves 1
  • From propranolol: Cool extremities, fatigue, sleep disturbance, and potential hypoglycemia masking in diabetics 2
  • These effects are additive only in terms of potential sedation, not pharmacologically synergistic

Critical Pitfalls to Avoid

Do Not Confuse with Beta-Blocker Combinations

  • Unlike combining propranolol with metoprolol or labetalol (which causes dangerous additive beta-blockade), etifoxine does not affect adrenergic receptors 3, 5
  • The risk profile is fundamentally different from beta-blocker polypharmacy

Do Not Assume Benzodiazepine-Like Interactions

  • Etifoxine does not potentiate propranolol's cardiovascular effects the way benzodiazepines might through excessive sedation 1
  • Etifoxine's lack of significant psychomotor impairment means less fall risk compared to benzodiazepine-beta-blocker combinations 1, 4

Avoid Abrupt Propranolol Discontinuation

  • If stopping propranolol, taper over 1-2 weeks regardless of etifoxine use to prevent rebound tachycardia and hypertension 2
  • This is a propranolol-specific concern, not interaction-related

Monitor for Propranolol's True Drug Interactions

  • CYP2D6 inhibitors (fluoxetine, paroxetine, duloxetine, bupropion) significantly increase propranolol levels and risk of bradycardia/hypotension 6
  • Epinephrine with propranolol can cause severe hypertension and bradycardia 7
  • These interactions are clinically significant, unlike the etifoxine combination

Advantages of This Combination Over Alternatives

Compared to Benzodiazepine-Beta-Blocker Combinations

  • Etifoxine does not cause dependence, withdrawal syndromes, or significant cognitive impairment 1, 4
  • After discontinuation, etifoxine shows continued improvement in anxiety symptoms, unlike alprazolam which shows rebound anxiety 4

Patient Selection

  • Particularly appropriate for patients requiring long-term anxiety management (>4 weeks) who also need beta-blockade 1, 4
  • Safer in elderly patients due to lower sedation and fall risk compared to benzodiazepines 1

References

Research

Etifoxine for pain patients with anxiety.

The Korean journal of pain, 2015

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Concurrent Use of Propranolol and Metoprolol

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Concurrent Use of Propranolol and Labetalol

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Propranolol-epinephrine interaction: a potential disaster.

Plastic and reconstructive surgery, 1983

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.